Retrospective Evaluation of The Rate of Cardiovascular Events in Type 2 Diabetic Patients Using Dapagliflozin, Empagliflozin and Exenatide

Bahriye Gültaş; Soner Cander; Özen Öz Gül

Makale detayları

Retrospective Evaluation of The Rate of Cardiovascular Events in Type 2 Diabetic Patients Using Dapagliflozin, Empagliflozin and Exenatide

Yazarlar:

Bahriye Gültaş | Soner Cander | Özen Öz Gül

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Endokrinoloji | İç Hastalıkları

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.51 Issue 1, pp.37-43

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

Türkçe

Document ID (Org No.):

2001348987

pISSN:

1300-414X

Anahtar kelimeler:

Özet:

 Cardiovascular diseases are more common in patients with type 2 diabetes than in those without diabetes. Large-scale studies have shown positive results regarding the cardiac effects of SGLT-2 inhibitors empagliflozin, dapagliflozin, etc. and GLP-1 analogs exenatide, etc.. This study aimed to evaluate and compare cardiovascular outcomes in patients using empagliflozin, dapagliflozin, or exenatide. Patients using a DPP-4 inhibitor linagliptin, known as cardiac neutral, were selected as the control group. This study was conducted with 400 patients, 100 of whom received treatment for at least twelve months from each treatment group linagliptin, exenatide, dapagliflozin, and empagliflozin. Myocardial infarction MI, cerebrovascular accident CVA, death due to cardiac causes, major cardiovascular event MACE: MI, CVA, and cardiac death, hospitalization due to heart failure, unstable anginaacute coronary syndrome ACS, peripheral artery disease and all-cause deaths were evaluated. When the total rates of all cardiovascular pathologies were examined, it was determined that they were 10 in the linagliptin group, 6 in the exenatide group, 4 in the dapagliflozin group and 6 in the empagliflozin group. When patients without a history of cardiac disease were compared, it was determined that the total cardiovascular pathology rates in the exenatide, dapagliflozin, and empagliflozin groups were statistically significantly reduced compared to the linagliptin group. In patients with a cardiac history, it was revealed that anginaACS was significantly reduced in the dapagliflozin and empagliflozin groups. These results show that exenatide, dapagliflozin, and empagliflozin molecules are helpful in the primary prevention of cardiac pathologies in our diabetic patients. Dapagliflozin and empagliflozin molecules may also be unique in the secondary protection of patients from cardiovascular pathologies.

 Cardiovascular diseases are more common in patients with type 2 diabetes than in those without diabetes. Large-scale studies have shown positive results regarding the cardiac effects of SGLT-2 inhibitors empagliflozin, dapagliflozin, etc. and GLP-1 analogs exenatide, etc.. This study aimed to evaluate and compare cardiovascular outcomes in patients using empagliflozin, dapagliflozin, or exenatide. Patients using a DPP-4 inhibitor linagliptin, known as cardiac neutral, were selected as the control group. This study was conducted with 400 patients, 100 of whom received treatment for at least twelve months from each treatment group linagliptin, exenatide, dapagliflozin, and empagliflozin. Myocardial infarction MI, cerebrovascular accident CVA, death due to cardiac causes, major cardiovascular event MACE: MI, CVA, and cardiac death, hospitalization due to heart failure, unstable anginaacute coronary syndrome ACS, peripheral artery disease and all-cause deaths were evaluated. When the total rates of all cardiovascular pathologies were examined, it was determined that they were 10 in the linagliptin group, 6 in the exenatide group, 4 in the dapagliflozin group and 6 in the empagliflozin group. When patients without a history of cardiac disease were compared, it was determined that the total cardiovascular pathology rates in the exenatide, dapagliflozin, and empagliflozin groups were statistically significantly reduced compared to the linagliptin group. In patients with a cardiac history, it was revealed that anginaACS was significantly reduced in the dapagliflozin and empagliflozin groups. These results show that exenatide, dapagliflozin, and empagliflozin molecules are helpful in the primary prevention of cardiac pathologies in our diabetic patients. Dapagliflozin and empagliflozin molecules may also be unique in the secondary protection of patients from cardiovascular pathologies.

 Cardiovascular diseases are more common in patients with type 2 diabetes than in those without diabetes. Large-scale studies have shown positive results regarding the cardiac effects of SGLT-2 inhibitors empagliflozin, dapagliflozin, etc. and GLP-1 analogs exenatide, etc.. This study aimed to evaluate and compare cardiovascular outcomes in patients using empagliflozin, dapagliflozin, or exenatide. Patients using a DPP-4 inhibitor linagliptin, known as cardiac neutral, were selected as the control group. This study was conducted with 400 patients, 100 of whom received treatment for at least twelve months from each treatment group linagliptin, exenatide, dapagliflozin, and empagliflozin. Myocardial infarction MI, cerebrovascular accident CVA, death due to cardiac causes, major cardiovascular event MACE: MI, CVA, and cardiac death, hospitalization due to heart failure, unstable anginaacute coronary syndrome ACS, peripheral artery disease and all-cause deaths were evaluated. When the total rates of all cardiovascular pathologies were examined, it was determined that they were 10 in the linagliptin group, 6 in the exenatide group, 4 in the dapagliflozin group and 6 in the empagliflozin group. When patients without a history of cardiac disease were compared, it was determined that the total cardiovascular pathology rates in the exenatide, dapagliflozin, and empagliflozin groups were statistically significantly reduced compared to the linagliptin group. In patients with a cardiac history, it was revealed that anginaACS was significantly reduced in the dapagliflozin and empagliflozin groups. These results show that exenatide, dapagliflozin, and empagliflozin molecules are helpful in the primary prevention of cardiac pathologies in our diabetic patients. Dapagliflozin and empagliflozin molecules may also be unique in the secondary protection of patients from cardiovascular pathologies.

 Tip 2 diyabet hastalarında kardiyovaskuler hastalıklar diyabeti olmayanlara göre daha yuksektir. SGLT-2 inhibitörlerinin empagliflozin, dapagliflozin vb. ve GLP-1 analoglarının exenatid vb. kardiyak etkilerine ilişkin olumlu sonuçlar veren geniş çaplı çalışmalar mevcuttur. Bu çalışmayla empagliflozin, dapagliflozin veya eksenatid kullanan hastalarda kardiyovaskuler sonuçları değerlendirmek ve karşılaştırmak amaçlanmıştır. Kontrol grubu olarak kardiyak açıdan nötr olduğu bilinen DPP-4 inhibitöru linagliptin kullanan hastalar seçilmiştir. Bu çalışma her tedavi grubundan linagliptin, eksenatid, dapagliflozin, empagliflozin en az on iki aydır tedavi gören 100 hasta olmak uzere toplam 400 hasta ile gerçekleştirilmiştir. Miyokard enfarktusu MI, serebrovaskuler olay SVO, kardiyak nedenlere bağlı ölum, majör kardiyovaskuler olay MACE: MI, SVO ve kardiyak ölum, kalp yetmezliği nedeniyle hastaneye yatış, kararsız anginaakut koroner sendrom AKS, periferik arter hastalığı ve tum nedenlere bağlı ölumler değerlendirilmiştir. Tum kardiyovaskuler patolojilerin toplam oranları incelendiğinde linagliptin grubunda 10, eksenatid grubunda 6, dapagliflozin grubunda 4 ve empagliflozin grubunda 6 olarak tespit edilmiştir. Kardiyak hastalık öykusu olmayan hastalar karşılaştırıldığında eksenatid, dapagliflozin ve empagliflozin grubunda toplam kardiyovaskuler patoloji oranlarının linagliptin grubuna göre istatistiksel olarak anlamlı derecede azaldığı saptanmıştır. Kardiyak öykusu olan hastalarda ise dapagliflozin ve empagliflozin grubunda anginaAKS tablosunun anlamlı derecede azaldığı ortaya konmuştur. Bu sonuçlar diyabet hastalarının kardiyak patolojilerden birincil korunmasında eksenatid, dapagliflozin ve empagliflozin molekullerinin faydalı olduğunu göstermektedir. Dapagliflozin ve empagliflozin molekulleirinin hastaların kardiyovaskuler patolojilerden sekonder korunmasında da tekili olabileceğini duşundurmektedir.

Makale detayları

Retrospective Evaluation of The Rate of Cardiovascular Events in Type 2 Diabetic Patients Using Dapagliflozin, Empagliflozin and Exenatide

Yazarlar:

Bahriye Gültaş | Soner Cander | Özen Öz Gül

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Endokrinoloji | İç Hastalıkları

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.51 Issue 1, pp.37-43

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

Türkçe

Document ID (Org No.):

2001348987

pISSN:

1300-414X

Linagliptin

Exenatide

Dapagliflozin

Empagliflozin

SGLT-2 inhibitors

Cardiovascular event: Linagliptin

Eksenatid

Dapagliflozin

Empagliflozin

SGLT-2 inhibitörleri

Kardiyovasküler Olay

Sayı

Makale detayları

Yazarlar: Bahriye Gültaş | Soner Cander | Özen Öz Gül

Yayıncı: Bursa Uludağ University

Ana Başlıklar: Endokrinoloji | İç Hastalıkları

Dergi: Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.51 Issue 1, pp.37-43

Belge Tipi: Makale

Yayın Tarihi: 5/2025

Belge Dili: Türkçe

Document ID (Org No.): 2001348987

pISSN: 1300-414X

Sayı

Yazarlar:

Bahriye Gültaş | Soner Cander | Özen Öz Gül

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Endokrinoloji | İç Hastalıkları

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.51 Issue 1, pp.37-43

Belge Tipi:

Makale

Yayın Tarihi:

5/2025

Belge Dili:

Türkçe

Document ID (Org No.):

2001348987

pISSN:

1300-414X